THE COMBINED USE OF CALCITONIN DOUBLING TIME AND F-18-FDG PET/CT IMPROVES PROGNOSTIC VALUES IN MEDULLARY THYROID CARCINOMA: THE CLINICAL UTILITY OF F-18-FDG PET/CT

Show simple item record

dc.contributor.author Yang, Ji H. [UNIFESP]
dc.contributor.author Camacho, Cleber P. [UNIFESP]
dc.contributor.author Lindsey, Susan C. [UNIFESP]
dc.contributor.author Valente, Flavia O. F. [UNIFESP]
dc.contributor.author Andreoni, Danielle M. [UNIFESP]
dc.contributor.author Yamaga, Lilian Y.
dc.contributor.author Wagner, Jairo
dc.contributor.author Biscolla, Rosa Paula M. [UNIFESP]
dc.contributor.author Maciel, Rui M. B. [UNIFESP]
dc.date.accessioned 2019-08-19T11:49:52Z
dc.date.available 2019-08-19T11:49:52Z
dc.date.issued 2017
dc.identifier http://dx.doi.org/10.4158/EP171806.OR
dc.identifier.citation Endocrine Practice. Jacksonville, v. 23, n. 8, p. 942-948, 2017.
dc.identifier.issn 1530-891X
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/51422
dc.description.abstract Objective: Calcitonin and carcinoembryonic antigen (CEA) doubling times are established prognostic markers in medullary thyroid cancer (MTC). On the other hand, F-18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) shows an increased rate of detection with high blood tumor marker levels in several cancers. This study aimed to analyze the ability of F-18-FDG PET/CT to determine prognosis in the follow-up of patients with MTC. Methods: Medical records of 17 patients with MTC who underwent F-18-FDG PET/CT were analyzed retrospectively. All patients were classified into two groups: stable disease or progressive disease. Results: Eight patients presented with progressive disease, and all of them showed F-18-FDG uptake (100%), compared to only 3 of 9 patients who presented in stable condition (33%). F-18-FDG PET/CT results were able to distinguish progressive from stable disease (P = .009). Calcitonin levels >4,020 pg/mL (P = .0004), CEA levels >26.8 ng/mL (P = .04), and a calcitonin doubling time <24.1 months (P = .015) were associated with progressive disease in our cohort. The proportion of variance explained that predicted progressive disease was 32% for F-18-FDG uptake, 27.1% for a calcitonin doubling time of 24.1 months, and 41.2% for doubling time plus F-18-FDG PET/CT. Conclusion: F-18-FDG uptake was able to distinguish progressive from stable disease. However, this tool should not replace the validated calcitonin doubling time, but rather the combination of information could improve the clinical re-assessment and better identify high-risk patients who require more careful surveillance. en
dc.description.sponsorship São Paulo State Research Foundation (FAPESP)
dc.description.sponsorship Fleury Group
dc.description.sponsorship Brazilian Ministry of Health
dc.description.sponsorship CAPES-Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.format.extent 942-948
dc.language.iso eng
dc.publisher Amer Assoc Clinical Endocrinologists
dc.rights Acesso restrito
dc.title THE COMBINED USE OF CALCITONIN DOUBLING TIME AND F-18-FDG PET/CT IMPROVES PROGNOSTIC VALUES IN MEDULLARY THYROID CARCINOMA: THE CLINICAL UTILITY OF F-18-FDG PET/CT en
dc.type Artigo
dc.description.affiliation Univ Fed São Paulo, Div Endocrinol, Multiple Endocrine Neoplasia Outpatient Clin, Escola Paulista Med,Dept Med, São Paulo, Brazil
dc.description.affiliation Univ Fed São Paulo, Div Endocrinol, Multiple Endocrine Neoplasia Outpatient Clin, Lab Mol & Translat Endocrinol,Escola Paulista Med, São Paulo, Brazil
dc.description.affiliation Hosp Israelita Albert Einstein, Imaging Dept, São Paulo, Brazil
dc.description.affiliationUnifesp Univ Fed São Paulo, Div Endocrinol, Multiple Endocrine Neoplasia Outpatient Clin, Escola Paulista Med,Dept Med, São Paulo, Brazil
dc.description.affiliationUnifesp Univ Fed São Paulo, Div Endocrinol, Multiple Endocrine Neoplasia Outpatient Clin, Lab Mol & Translat Endocrinol,Escola Paulista Med, São Paulo, Brazil
dc.description.sponsorshipID FAPESP: [2006/60402-1
dc.description.sponsorshipID FAPESP: 2010/51547-1
dc.description.sponsorshipID FAPESP: 2009/50575-4
dc.description.sponsorshipID Fleury Group: 12518
dc.description.sponsorshipID Brazilian Ministry of Health: 25000.168513/2008-11
dc.identifier.doi 10.4158/EP171806.OR
dc.description.source Web of Science
dc.identifier.wos WOS:000411114800006



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account